5Greipp PR.Bisphosphanates for myeloma-current approach to treatment[J].Myeloma Today,1998,10:5.
6Berenson JR,Lichtenstein A,Porter L,et al.Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma[J].N Engl J Med,1996,334:448.
7Henick K,Vescio RA,Berenson JR.Recent advances in the treatment multiple myeloma[J].Curr Top Hematol,1998,5:254.
8Zimolo Z,Wesolowski G,Godan GA.Acid extrusion is induced by osteoclast attachment to bone:inhibition by alendronate and calcitonin[J].J Clin Invest,1995,96:2277-2283.
9Hughes DE,Wright KR,Uy HL,et al.Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo[J].J Bone Miner Res,1995,10:1478-1487.
10Luckman SP,Hughes DE,Coxon FP,et al.Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent poat-translational prenylation of GTP-binding proteins,including Ras[J].J Bone Miner Res,1998,13:581-589.
4Johhnson J R,Williams G,Pazdur R.End Points and United States Food and Drug Administration Approved of Oncology Drug[J].J Clin Oncol,2003,21:1401-1411.
5Green J R,Muller K,Jaeggi K A.Preclinical Pharmacology of CGP 42'446:a New Potent Heterocyclic Bisphosphonate Compound[J].J Bone Miner Rres,1994,9:745-751.
6Mckeage K,Plosker G L.Zoledronic Acid:a Pharmacoeconomic Review of Its Use in the Management of Bone Metastases[J].Pharmacoeconomics,2008,26:251-268.
7King A E,Umland E M.Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates[J].Pharmacotherapy,2008,28:667-677.
